Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium

Journal of Clinical Oncology

Volumn 27, Issue 25, 2009, Pages 4062-4067

  Milowsky, Matthew I ^a   Nanus, David M ^a   Maluf, Fernando C ^a   Mironov, Svetlana ^a   Shi, Weiji ^a   Iasonos, Alexia ^a   Riches, Jamie ^a   Regazzi, Ashley ^a   Bajorin, Dean F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; MESNA; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; VOMITING; BLADDER TUMOR; CANCER INVASION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; TIME; TREATMENT OUTCOME; UROTHELIUM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; IFOSFAMIDE; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PACLITAXEL; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 70249128736     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.2241     Document Type: Article

References (27)

1. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 10:1066-1073, 1992
2. Logothetis CJ, Dexeus F, Sella A, et al: A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastatic urothelial tumors. J Clin Oncol 8:1050-1055, 1990
3. Saxman S, Propert K, Einhorn L, et al: Long term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial cancer: A cooperative group study. J Clin Oncol 15:2564-2569, 1997
4. von der Maase H, Hansen SW, Roberts JT, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068-3077, 2000
5. von der Maase H, Sengelov L, Roberts JT, et al: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602-4608, 2005
6. Roth BJ, Dreicer R, Einhorn LH, et al: Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12:2264-2270, 1994
7. Gad-el-Mawla N, Hamza MR, Zikri ZK, et al: Chemotherapy in invasive carcinoma of the bladder: A review of phase II trials in Egypt. Acta Oncol 28:73-76, 1989
8. Reference deleted
9. Pronzato P, Vigani A, Pensa F, et al: Secondline chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. Am J Clin Oncol 20:519-521, 1997
10. Witte RS, Elson P, Bono B, et al: Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 15:589-593, 1997
11. Bajorin DF, McCaffrey JA, Hilton S, et al: Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: A phase II trial. J Clin Oncol 16:2722-2727, 1998
12. Bajorin DF, McCaffrey JA, Dodd PM, et al: Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: Final report of a phase II trial evaluating two dosing schedules. Cancer 88:1671-1678, 2000
13. Norton L, Simon R: The Norton-Simon hypothesis revisited. Cancer Treat Rep 70:163-169, 1986
14. Norton L: Conceptual basis for advances in the systemic drug therapy of breast cancer. Semin Oncol 24:S11-S12, 1997
15. Dodd PM, McCaffrey JA, Hilton S, et al: Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J Clin Oncol 18:840-846, 2000
16. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Statist Assoc 53:457-481, 1958
17. Bajorin DF, Dodd PM, Mazumdar M, et al: Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173-3181, 1999
18. Donat SM, Herr HW, Bajorin DF, et al: Methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and cystectomy for unresectable bladder cancer. J Urol 156:368-371, 1996
19. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003
20. Logothetis CJ, Finn LD, Smith T, et al: Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: Results of a randomized trial. J Clin Oncol 13:2272-2277, 1995
21. Seidman AD, Scher HI, Gabrilove JL, et al: Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 11:408-414, 1993
22. Gabrilove JL, Jakubowski A, Scher H, et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414-1422, 1988
23. Moore MJ, Tannock IF, Iscoe N, et al: A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) + GM-CSF in patients with advanced transitional cell carcinoma. Proc Am Soc Clin Oncol 11:199a, 1992
24. Loehrer PJ Sr, Elson P, Dreicer R, et al: Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: An Eastern Cooperative Oncology Group trial. J Clin Oncol 12:483-488, 1994
25. Sternberg CN, de Mulder PH, van Oosterom AT, et al: Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors. Ann Oncol 4:403-407, 1993
26. Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/ cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy: EORTC 30987/Intergroup Study. J Clin Oncol 25:242s, 2007 (suppl; abstr LBA5030)
27. Sternberg C, Yagoda A, Scher HI, et al: Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium. Cancer 64:2448-2458, 1989